Menu ×

Global Auto-Injector Market to Grow with a CAGR of 13.9% During 2021-2030; Increasing Prevalence of Diabetes and Allergies Worldwide to Promote Market Growth

  • Text Size:

Nester published a report titled Auto-Injector Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of the global auto-injector market in terms of market segmentation by type, route of administration, drug type, application, demography, distribution channel, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global auto-injector market is anticipated to grow with a CAGR of 13.9% during the forecast period, i.e., 2021-2030. The market is segmented by drug type into epinephrine, insulin, Rebif, and others, out of which, the epinephrine segment registered the largest revenue of USD 857.2 Million in the year 2020. Moreover, the segment is expected to touch a revenue of USD 3230.8 Million by the end of 2030. The market is also segmented by type into disposable auto-injector, and reusable auto-injector. Out of these, the disposable auto-injector segment is projected to grow with the highest CAGR of 14% during the forecast period.

The global auto-injector market is estimated to garner a revenue of USD 11354.6 Million by the end of 2030, up from a revenue of USD 3117.4 Million in the year 2020. Growing concern for the rising prevalence of allergies globally, coupled with the increasing cases of diabetes, are some of the major factors anticipated to drive the market growth. Additionally, the numerous benefits associated with the use of auto-injectors is also projected to contribute to the market growth during the forecast period.

The global auto-injectors market is segmented by region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, the market in North America is anticipated to garner the largest market revenue of USD 4404.5 Million by the end of 2030, backed by the presence of a strong healthcare network in the region, especially in the United States, and for the increasing awareness for the prevention and diagnosis of allergic and diabetes diseases. Moreover, amongst the countries in the region, the market in the U.S. is projected to hold the highest market share and also grow with the highest CAGR of 14.2% during the forecast period.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Growing Prevalence of Allergic Diseases Worldwide

In one of the statistics by the Asthma and Allergy Foundation of America (AAFA), allergic conditions are one of the most common health issues that affects both adult and children in the United States. Additionally, the statistics also stated that 30,000 emergency room visits were estimated as a result of anaphylaxis to food.

The prevalence of allergic diseases is a major concern amongst individuals worldwide. To treat allergic diseases such as anaphylaxis, which is a severe and a life-threatening disease, patients are prescribed with epinephrine auto injectors, as this is known to be an effective solution for the cure of the disease. Owing to such a factor, the demand for auto-injectors is projected to grow significantly, and in turn drive the market growth in the coming years.

However, the availability of low-cost alternatives is expected to operate as key restraint to the growth of global auto-injector market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global auto-injector market which includes company profiling of Pfizer Inc., BD, Adamis Pharmaceuticals Corporation, Biogen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Antares Pharma, Inc., Sanofi S.A., Ypsomed AG, SHL Medical AG, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global auto-injector market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.


Related Press Releases

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved